KRW 1446.0
(-0.69%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 21.49 Billion KRW | -31.89% |
2022 | 31.56 Billion KRW | 30.2% |
2021 | 24.24 Billion KRW | 140.84% |
2020 | 10.06 Billion KRW | 350.95% |
2019 | 2.23 Billion KRW | 77.34% |
2018 | 1.25 Billion KRW | 31.7% |
2017 | 955.78 Million KRW | -7.1% |
2016 | 1.02 Billion KRW | -60.25% |
2015 | 2.58 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 20.95 Billion KRW | -2.51% |
2024 Q2 | 15.37 Billion KRW | -26.64% |
2023 Q2 | 18.99 Billion KRW | -40.17% |
2023 Q1 | 31.74 Billion KRW | 0.56% |
2023 FY | 21.49 Billion KRW | -31.89% |
2023 Q4 | 21.49 Billion KRW | 5.43% |
2023 Q3 | 20.39 Billion KRW | 7.37% |
2022 FY | 31.56 Billion KRW | 30.2% |
2022 Q4 | 31.56 Billion KRW | 4.19% |
2022 Q3 | 30.29 Billion KRW | 4.4% |
2022 Q2 | 29.01 Billion KRW | 31.78% |
2022 Q1 | 22.02 Billion KRW | -9.17% |
2021 Q2 | 26.31 Billion KRW | 179.76% |
2021 Q3 | 24.13 Billion KRW | -8.28% |
2021 FY | 24.24 Billion KRW | 140.84% |
2021 Q4 | 24.24 Billion KRW | 0.46% |
2021 Q1 | 9.4 Billion KRW | -6.57% |
2020 Q3 | 9.43 Billion KRW | 0.0% |
2020 FY | 10.06 Billion KRW | 350.95% |
2020 Q1 | - KRW | -100.0% |
2020 Q4 | 10.06 Billion KRW | 6.75% |
2019 Q4 | 2.23 Billion KRW | 0.0% |
2019 FY | 2.23 Billion KRW | 77.34% |
2018 FY | 1.25 Billion KRW | 31.7% |
2017 FY | 955.78 Million KRW | -7.1% |
2016 FY | 1.02 Billion KRW | -60.25% |
2015 FY | 2.58 Billion KRW | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 27.25 Billion KRW | 21.124% |
InBody Co.,Ltd | 24.62 Billion KRW | 12.683% |
Curexo Inc. | 6.94 Billion KRW | -209.731% |
Seegene, Inc. | 221.05 Billion KRW | 90.274% |
i-SENS, Inc. | 195.32 Billion KRW | 88.993% |
Ray Co., Ltd. | 128.35 Billion KRW | 83.251% |
Sugentech Inc. | 20.73 Billion KRW | -3.697% |
L&C Bio Co., Ltd | 105.37 Billion KRW | 79.598% |